Skip to main content

Nijhawan Pardeep's Form 4 filing

Edesa Biotech, Inc. (EDSA) · filed Mar 2, 2026

Accession no.
0001171843-26-001267
Filed
Mar 2, 2026
Trade date
Feb 26-Mar 2, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market purchases total $99.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Nijhawan PardeepCIK 0001777962Director, Officer (Chief Executive Officer), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 26, 2026Common SharesPPurchaseAcquired+20,571$1.58F1+$32,502.18615,797Direct
Mar 2, 2026Common SharesAGrant or awardAcquired+10,016$0.00F2$0625,813Direct
Feb 27, 2026Common SharesPPurchaseAcquired+30,000$2.22F3+$66,600371,702Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.54 to $1.58 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.22 to $2.2295 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)